1H MR spectroscopy of brain tumours and masses

NMR in Biomedicine

Volumn 16, Issue 3, 2003, Pages 123-131

  Howe, Franklyn A ^a   Opstad, Kirstie S ^a  

^a IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

Author keywords

1H MRS; Brain tumour; Diagnosis; Prognosis

Indexed keywords

BRAIN; IMAGING TECHNIQUES; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; RADIOLOGY;

BIOMEDICINE;

TUMORS;

BRAIN TUMOR; CANCER GRADING; DIAGNOSTIC ACCURACY; HUMAN; NON INVASIVE MEASUREMENT; PRIORITY JOURNAL; PROGNOSIS; PROTON NUCLEAR MAGNETIC RESONANCE; RADIODIAGNOSIS; REVIEW; TREATMENT OUTCOME; TREATMENT PLANNING; TUMOR BIOPSY; TUMOR CLASSIFICATION; TUMOR VOLUME; ANIMAL; CANCER STAGING; CLASSIFICATION; METHODOLOGY; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PATHOLOGY;

PROTON; TUMOR MARKER;

ANIMALS; BRAIN NEOPLASMS; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; NEOPLASM STAGING; PROTONS; TUMOR MARKERS, BIOLOGICAL;

EID: 0043131975     PISSN: 09523480     EISSN: None     Source Type: Journal    
DOI: 10.1002/nbm.822     Document Type: Review

References (91)

1. Greenberg HS, Chandler WF, Sandler HM. Brain Tumours. Oxford University Press: New York, 1999; 153, 181, 281-282.
2. Yu X, Liu Z, Tian Z, Li S, Huang H, Xiu B, Zhao Q, Liu L, Jing W. Stereotactic biopsy for intracranial space-occupying lesions: clinical analysis of 550 cases. Stereotact. Funct. Neurosurg. 2000; 75: 103-108.
3. Alesch F, Pappaterra J, Trattnig S, Koos WT. The role of stereotactic biopsy in radiosurgery. Acta Neurochir. Suppl. (Wien) 1995; 63: 20-24.
4. Kondziola D, Lunsford LD, Martinez AJ. Unreliability of contemporary imaging in evaluating suspected adult supratentorial (low-grade) astrocytoma. J. Neurosurg. 1993; 79: 533-536.
5. Bernstein M, Parrent AG. Complications of CT-guided stereotactic biopsy of intra-axial brain lesions. J. Neurosurg. 1994; 81: 165-168.
6. Ross B, Michaelis T. Clinical applications of magnetic resonance spectroscopy. Magn. Reson. Q. 1994; 10: 191-247.
7. Howe FA. Magnetic resonance spectroscopy in vivo. In Principles and Practice of MRI: Selected Topics, Markisz JA, Whalen JP (eds). Appleton & Lange, 1998; 17-107.
8. Tzika AA, Zarifi MK, Goumnerova L, Astrakas LG, Zurakowski D, Young-Poussaint T, Anthony DC, Scott RM, Black P McL. Neuroimaging in pediatric brain tumors: Gd-DTPA enhanced, hemodynamic, and diffusion MR imaging compared with MR spectroscopic imaging. Am. J. Neuroradiol. 2002; 23: 233-333.
9. Wald LL, Nelson SJ, Day MR, Noworolski SE, Henry RG, Huhn SL, Chang S, Prados MD, Sneed PK, Larson DA, Wara WM, McDermott M, Dillon WP, Gutin PH, Vigneron D. Serial proton magnetic resonance spectroscopy imaging of glioblastoma multiforme after brachytherapy. J. Neurosurg. 1997; 87: 525-534.
10. Law M, Cha S, Knopp EA, Johnson G, Arnett J, Litt AW. High-grade gliomas and solitary metastases: differentiation by using perfusion and proton spectroscopic MR imaging. Radiology 2002; 222: 715-721.
11. 1H MRSI. J. Magn. Reson. Imag. 2002; 16: 464-476.
12. Burtscher IM, Skagerberg G, Geijer B, Englund E, Stahlberg F, Holtas S. Proton MR spectroscopy and preoperative diagnostic accuracy: an evaluation of intracranial mass lesions characterized by stereotactic biopsy findings. Am. J. Neuroradiol. 2000; 21: 84-93.
13. Dowling C, Bollen AW, Noworolski SM, McDermott MW, Barbaro NM, Day MR, Henry RG, Chang SM, Dillon WP, Nelson SJ, Vigneron DB. Preoperative proton MR spectroscopic imaging of brain tumors: correlation with histopathologic analysis of resection specimens. Am. J. Neuroradiol. 2001; 22: 604-612.
14. Liu H, Hall WA, Martin AJ, Maxwell RE, Truwit CL. MR-guided and MR-monitored neurosurgical procedures at 1.5 T. J. Comput. Assist. Tomogr. 2000; 24: 909-918.
15. Ott D, Hennig J, Ernst T. Human brain tumours: assessment with in vivo proton MR spectroscopy. Radiology 1993; 186: 745-752.
16. Paulus W, Pfeiffer J. Intratumoral histologic heterogeneity of gliomas. A quantitative study. Cancer 1989; 64: 442-447.
17. de Edelenyi FS, Rubin C, Esteve F, Grand S, Decorps M, Lefournier V, le Bas J-F, Remy C. A new approach for analysing proton magnetic resonance spectroscopic images of brain tumors: nosologic images. Nat. Med. 2000; 6: 1287-1289.
18. Preul MC, Caramanos Z, Leblanc R, Villemure JG, Arnold DL. Using pattern recognition of in vivo proton MRSI data to improve the diagnosis and surgical management of patients with brain tumors. NMR Biomed. 1998; 11: 192-200.
19. 1H magnetic resonance spectroscopy. Magn. Reson. Med. 2003; 49: 223-232.
20. 1H brain tumour spectra: a multicentre study. Magn. Reson. Med. 2003; 49: 29-36.
21. 1H magnetic resonance metabolite phenotypes. Neuroreport 1996; 7: 1597-1600.
22. 1H magnetic resonance spectroscopic imaging. Ann. Neurol. 1998; 44: 273-278.
23. Poptani H, Kaartinen J, Gupta RK, Niemitz M, Hiltunen Y, Kauppinen. Diagnostic assessment of brain tumors and non-neoplastic brain disorders in vivo using proton nuclear magnetic resonance spectroscopy and artificial neural networks. J. Cancer Res. Clin. Oncol. 1999; 125: 343-349.
24. 1H NMR spectroscopy for three types of human brain and nervous system tumours. NMR Biomed. 1996; 8: 253-264.
25. Kinoshita Y, Kajiwara H, Yokota A, Koga Y. Proton magnetic resonance spectroscopy of brain tumors: an in vitro study. Neurosurgery 1994; 35: 606-614.
26. 1H NMR spectroscopy in vivo and in vitro. J. Neurochem. 1994; 63: 1538-1543.
27. 1H MRS of high grade astrocytomas: mobile lipid accumulation in necrotic tissue. NMR Biomed. 1994; 7: 149-155.
28. Cheng LL, Chang I-W, Louis DN, Gonzalez RG. Correlation of high-resolution magic angle spinning proton magnetic resonance spectroscopy with histopathology of intact human brain tumor specimens. Cancer Res. 1998; 58: 1825-1832.
29. 1H HR-MAS spectroscopy of intact biopsy samples in vivo. MAGMA 1999; 8: 121-128.
30. Yeung DKW, Yang W-T, Tse GMK. Breast cancer: in vivo proton MR spectroscopy in the characterisation of histopathologic subtypes and preliminary observations in axillary node metastases. Radiology 2002; 225: 190-197.
31. Swanson MG, Vigneron DB, Tran T-K C, Sailasuta N, Hurd RE, Kurhanewicz J. Single-voxel oversampled J-resolved spectroscopy of in vivo human prostate tissue. Magn. Reson. Med. 2001; 45: 973-980.
32. Negendank WG, Padavic-Shaller KA, Li CW, Murphy-Boesch J, Stoyanova R, Krigel RL, Schilder RJ, Smith MR, Brown TR. Metabolic characterisation of non-Hodgkin's lymphomas in vivo with the use of proton-decoupled phosphorus magnetic resonance spectroscopy. Cancer Res. 1995; 55: 3286-3294.
33. 1H magnetic resonance spectroscopy for discrimination of primary brain tumours. Invest. Radiol. 1999; 34: 230-235.
34. Herminghaus S, Pilatus U, Moller-Hartman W, Raab P, Lanfermann H, Schlote W, Zanella F. Increased choline levels coincide with enhanced proliferative activity of human neuroepithelial brain tumors. NMR Biomed. 2002; 15: 385-392.
35. Shimizu H, Kumabe T, Shirane R, Yoshimoto. Correlation between choline level measured by proton MR spectroscopy and Ki-67 labelling index in gliomas. Am. J. Neuroradiol. 2000; 21: 659-665.
36. Shiino A, Nakasu S, Matsuda M, Handa J, Morikawa S, Inubushi T. Noninvasive evaluation for the malignant potential of intracranial meningiomas performed using proton magnetic resonance spectroscopy. J. Neurosurg. 1999; 91: 928-934.
37. Manton DJ, Lowry M, Blackband SJ, Horsman A. Determination of proton metabolite concentrations and relaxation parameters in normal human brain and intracranial tumours. NMR Biomed. 1995; 8: 104-112.
38. 1H MRS to clinical brain tumour diagnosis. J. Neurosurg. 2002; 16: 329-334.
39. Ishimaru H, Morikawa M, Iwanaga S, Kaminogo M, Ochi M, Hayashi K. Differentiation between high-grade glioma and metastatic brain tumor using single-voxel proton MR spectroscopy. Eur. Radiol. 2001; 9: 1784-1791.
40. Castillo M, Smith JK, Kwock L. Correlation of myo-inositol levels and grading of cerebral astrocytomas. Am. J. Neuroradiol. 2000; 21: 1645-1649.
41. Barba I, Moreno A, Martinez-Perez I, Tate AR, Cabanas ME, Baquero M, Capdevila A, Arus C. Magnetic resonance spectroscopy of brain hemangiopericytomas: high myo-inositol concentrations and discrimination from meningiomas. J. Neurosurg. 2001; 94: 55-60.
42. Norfray JF, Tomita T, Byrd SE, Ross BD, Berger PA, Miller RS. Clinical impact of MR spectroscopy when MR imaging is indeterminate for pediatric brain tumors. Am. J. Roentgenol. 1999; 173: 119-125.
43. Mader I, Roser W, Hagberg G, Schneider M, Sauter R, Seelig J, Radue EW, Steinbrich W. Proton chemical shift imaging, metabolic maps, and single voxel spectroscopy of glial brain tumours. MAGMA 1996; 4: 139-150.
44. 1H MRS. Magn. Reson. Med. 2003; 49: 632-637.
45. Stubbs M, Veech RL, Griffiths JR. Tumour metabolism: the lessons of magnetic resonance spectroscopy. Adv. Enzyme Regul. 1995; 35: 101-115.
46. Kugel H, Heindel W, Ernestus R-I, Bunke J, du Mesnil R, Friedmann G. Human brain tumours: spectral patterns detected with localized H-1 MR spectroscopy. Radiology 1992; 183: 701-709.
47. Alger JR, Frank JA, Bizzi A, Fulham MJ, DeSouza BX, Duhaney MO, Inscoe SW, Black JL, van Zijl PCM, Moonen CTW, Di Chiro G. Metabolism of human gliomas: assessment with H-1 MR spectroscopy and F-18 fluorodeoxyglucose PET. Radiology 1990; 177: 633-641.
48. Auer DP, Gossl C, Schirmer T, Czisch M. Improved analysis of 1H-MR spectra in the presence of mobile lipids. Magn. Reson. Med. 2001; 46: 615-618.
49. Negendank WG, Sauter R, Brown TR, Evelhoch JL, Falini A, Gotsis ED, Heerschap A, Kamada K, Lee BCP, Mengeot MM, Moser E, Padavic-Shaller KA, Sanders JA, Spraggins TA, Stillman AE, Terwey B, Vogl TJ, Wicklow K, Zimmerman RA. Proton magnetic resonance spectroscopy in patients with glial tumours: a multicenter study. J. Neurosurg. 1996; 84: 449-458.
50. 1H magnetic resonance of human tumours. Analysis of the transverse relaxation of the methylene protons using continuous distributions of relaxation times. NMR Biomed. 1989; 2: 142-150.
51. Barba I, Cabanas ME, Arus C. The relationship between nuclear magnetic resonance-visible lipids, lipid droplets, and cell proliferation in cultured C6 cells. Cancer Res. 1999; 59: 1861-1868.
52. 1H MRS detects polyunsaturated fatty acid accumulation during gene therapy of glioma: implications for the in vivo detection of apoptosis. Nat. Med. 1999; 5: 1323-1327.
53. 1H MRS of human brain tumour and normal glial cells. NMR Biomed. 1994; 7: 111-120.
54. Sijens PE, van Dijk P, Oudkerk M. Correlation between choline level and Gd-DTPA enhancement in patients with brain metastases of mammary carcinoma. Magn. Reson. Med. 1994; 32: 549-555.
55. Ricci PE, Pitt A, Keller PJ, Coons SW, Heiserman JE. Effect of voxel position on single-voxel MR spectroscopy findings. Am. J. Neuroradiol. 2000; 21: 367-374.
56. Herminghaus S, Dierks T, Pilatus U, Moller-Hartmann W, Wittsack J, Marquardt G, Labisch C, Lanfermann H, Schlote W, Zanella FE. Determination of histopathological tumor grade in neuroepithelial brain tumors by using spectral pattern analysis of in vivo spectroscopic data. J. Neurosurg. 2003; 98: 74-81.
57. 1H MR spectroscopy monitoring of changes in choline peak area and line shape after Gd-contrast administration. Magn. Reson. Imag. 1998; 16: 1273-1280.
58. Lin AP and Ross BD. Short-echo time proton MR spectroscopy in the presence of gadolinium. J. Comput. Assist. Tomogr. 2001; 25: 705-712.
59. Smith JK, Kwock L, Castillo M. Effects of contrast material on single volume proton MR spectroscopy. Am. J. Neuroradiol. 2000; 21: 1084-1089.
60. 1 weighted choline signal in human brain tumours. Magn. Reson. Imag. 2002; 20: 127-130.
61. Nelson SJ. Analysis of volume MRI and MR spectroscopic imaging data for the evaluation of patients with brain tumors. Magn. Reson. Med. 2001; 46: 228-239.
62. Vigneron D, Bollen A, McDermott M, Wald L, Day M, Moyher-Noworolski S, Henry R, Chang S, Berger M, Dillon W, Nelson S. Three-dimensional magnetic resonance spectroscopic imaging of histologically confirmed brain tumors. Magn. Reson. Imag. 2001; 19: 89-101.
63. Majos C, Alonso J, Aguilera C, Serralonga M, Acebes JJ, Arus C, Gili J. Adult primitive neuroectodermal tumor: proton MR spectroscopic findings with possible applications for differential diagnosis. Radiology 2002; 225: 556-566.
64. Butzen J, Prost R, Chetty V, Donahue K, Neppl R, Bowen W, Li S-J, Haughton V, Mark L, Kim T, Mueller W, Meyer G, Krower H, Rand S. Discrimination between neoplastic and nonneoplastic brain lesions by use of proton MR spectroscopy: the limits of accuracy with a logistic regression model. Am. J. Neuroradiol. 2000; 21: 1213-1219.
65. Underwood J, Tate AR, Luckin R, Majos C, Capdevila A, Howe F, Griffiths J, Arus C. A prototype decision support system for MR spectroscopy-assisted diagnosis of brain tumours. Medinfo 2001; 10: 561-565.
66. McKnight TR, Noworolski SM, Vigneron DB, Nelson SJ. An automated technique for the quantitative assessment of 3D-MRSI data from patients with glioma. J. Magn. Reson. Imag. 2001; 13: 167-177.
67. McKnight TR, von dem Bussche MH, Vigneron DB, Lu Y, Berger MS, McDermott MW, Dillon WP, Graves EE, Pirzkall A, Nelson SJ. Histopathological validation of a three-dimensional magnetic resonance spectroscopy index as a predictor of tumor presence. J. Neurosurg. 2002; 97: 794-802.
68. Tran TK, Vigneron DB, Sailasuta N, Tropp J, Le Roux P, Kurhanewicz J, Nelson S, Hurd R. Very selective suppression pulses for clinical MRSI studies of brain and prostate cancer. Magn. Reson. Med. 2000; 43: 23-33.
69. Martin AJ, Liu H, Hall WA, Truwit CL. Preliminary assessment of turbo spectroscopic imaging for targeting in brain biopsy. Am. J. Neuroradiol. 2001; 22: 959-968.
70. Alger JR, Frew AJ, Cloughesy TF, del Vecchio W, Villablanca JP, Curran JG. Novel methodology for the archiving and interactive reading of clinical magnetic resonance spectroscopic imaging. Magn. Reson. Med. 2002; 48: 411-418.
71. Gill SS, Thomas DGT, van Bruggen N, Gadian DG, Peden CJ, Bell JD, Cox J, Menon DK, Iles RA, Bryant DJ, Coutts GA. Proton MR spectroscopy of intracranial tumours: in vivo and in vitro studies. J. Comput. Assist. Tomogr. 1990; 14: 497-504.
72. Lazareff JA, Bockhorst KH, Curran J, Olmstead C, Alger JR. Pediatric low-grade gliomas: prognosis with proton magnetic resonance spectroscopic imaging. Neurosurgery 1998; 43: 809-817.
73. Warren KE, Frank JA, Black JL, Hill RS, Duyn JH, Aikin AA, Lewis BK, Adamson PC, Balis FM. Proton magnetic resonance spectroscopic imaging in children with recurrent primary brain tumors. J. Clin. Oncol. 2000; 18: 1020-1026.
74. Wilken B, Dechent P, Herms J, Maxton C, Markakis E, Hanefeld F, Frahm J. Quantitative proton magnetic resonance spectroscopy of focal brain lesions. Pediatr. Neurol. 2000; 23: 22-31.
75. Cecil KM, Jones BV. Magnetic resonance spectroscopy of the pediatric brain. Top. Magn. Reson. Imag. 2001; 12: 435-452.
76. Krouwer HGJ, Kim TA, Rand SD, Prost RW, Haughton VM, Ho K-C, Jaradeh SS, Meyer GA, Blindauer KA, Cusick GLM, Walsh PR. Singel-voxel proton MR spectroscopy of nonneoplastic brain lesions suggestive of a neoplasm. Am. J. Neuroradiol. 1998; 19: 1695-1703.
77. Saindane AM, Cha S, Law M, Xue X, Knopp EA, Zagzag D. Proton MR spectroscopy of tumefactive demyelinating lesions. Am. J. Neuroradiol. 2002; 23: 1378-1386.
78. Saunders DE, Howe FA, van den Boogaart A, McLean MA, Griffiths JR, Brown MM. Proton spectroscopy in acute and chronic stroke. Stroke 1995; 26: 1007-1013.
79. Davie CA, Hawkins CP, Barker GJ, Brennan A, Tofts PS, Miller DH, McDonald WI. Serial proton magnetic resonance spectroscopy in acute multiple sclerosis lesions. Brain 1994; 117: 49-58.
80. Kim SH, Chang K-H, Song IC, Han MH, Kim HC, Kang HS, Han MC. Brain abscess and brain tumor: discrimination with in vivo H-1 MR spectroscopy. Radiology 1997; 204: 239-245.
81. Graves EE, Nelson SJ, Vigneron DB, Verhey L, McDermott M, Larson D, Chang S, Prados MD, Dillon WP. Serial proton MR spectroscopic imaging of recurrent malignant gliomas after gamma knife radiosurgery. Am. J. Neuroradiol. 2001; 22: 613-624.
82. Taylor JS, Langston JW, Reddick WE, Kingsley PB, Ogg RJ, Oui MH, Kun LE, Jenkins JJ, Chen G, Ochs JJ, Sanford RA, Heidman RL. Clinical value of proton magnetic resonance spectroscopy for differentiating recurrent or residual brain tumour from delayed cerebral necrosis. Int. J. Radiat. Oncol. Biol. Phys. 1996; 36: 1251-1261.
83. Rock JP, Hearshen D, Scarpace L, Crotesu D, Gutierrez J, Fisher JL, Rosenblum ML. Mikkelsen. Correlations between magnetic resonance spectroscopy and image-guided histopathology, with special attention to radiation necrosis. Neurosurgery 2002; 51: 912-920.
84. Tedeschi G, Lundbom N, Raman R, Bonavita S, Duyn JH, Alger JR, Di Chiro G. Increased choline signal coinciding with malignant degeneration of cerebral gliomas: a serial proton magnetic resonance spectroscopy imaging study. J. Neurosurg. 1997; 87: 516-524.
85. 1H magnetic resonance spectroscopic imaging as a tool for evaluating patients with recurrent gliomas begin considered for treatment with gamma knife radiosurgery. In: Proceedings of the 10th Annual Meeting of ISMRM, Honolulu, Hawai'i, USA, 2002; 574.
86. Moller-Hartmann W, Herminghaus S, Krings T, Marquardt G, Lanfermann H, Pilatus U, Zanella FE. Clinical application of proton magnetic resonance spectroscopy in the diagnosis of intracranial mass lesions. Neuroradiology 2002; 44: 371-378.
87. Rabinov JD, Lee PL, Barker FG, Louis DN, Harsh GR, Cosgrove GR, Chiocca EA, Thornton AF, Loeffler JS, Henson JW, Gonzalez RG. In vivo 3-T MR spectroscopy in the distinction of recurrent glioma versus radiation effects: initial experience. Radiology 2002; 225: 871-879.
88. 1H NMR spectroscopy of the human brain at 7 T. Magn. Reson. Med. 2001; 46: 451-456.
89. Rickman DS, Bobek MP, Misek DE, Kuick R, Blaivas M, Kurnit DM, Taylor J, Hanash SM. Distinctive molecular profiles of high-grade and low-grade gliomas based on oligonucleotide microarray analysis. Cancer Res. 2001; 61: 6885-6891.
90. Sallinen S-L, Sallinen PK, Haapasalo HK, Helin HJ, Helen PT, Schraml P, Kallioniemi O-P, Kononen J. Identification of differentially expressed genes in human gliomas by DNA microarray and tissue chip techniques. Cancer Res. 2001; 60: 6617-6622.
91. Pomeroy SL, Tamayo P, Gaasenbeek M, Sturla LM, Angelo McLaughlin ME, Kim JYH, Goumnerova LC, Black PM, Lau C, Allen JC, Zagzag D, Olson JM, Curran TY, Wetmore C, Blegel JA, Poggio T, Mukherjee S, Rifkin R, Califano A, Stoitzky G, Louis D, Mesirov JP, Lander ES, Golub T. Prediction of central nervous system embryonal tumour outcome based on gene expression. Nature 2002; 415: 436-442.